A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma

Full Title

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma


About 10 to 15 percent of patients with Hodgkin lymphoma are over age 60. However, due to more aggressive disease and less tolerance of standard chemotherapy, patients with Hodgkin lymphoma do not fare as well as younger patients with standard chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of giving the drug brentuximab (also called SGN-35) before and after therapy with standard chemotherapy that includes doxorubicin (Adriamycin), vinblastine, and dacarbazine in older patients with previously untreated Hodgkin lymphoma.

Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells (including Hodgkin lymphoma) called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Brentuximab is already approved for the treatment of certain patients with Hodgkin lymphoma.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have previously untreated stage II-IV Hodgkin lymphoma.
  • This study is open to patients age 60 and older.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.

For more information about this study and to inquire about eligibility, please contact Dr. Paul A. Hamlin at 212-639-6143.